Концепция лечения сахарного диабета 2 типа публикации

Концепция лечения сахарного диабета 2 типа публикации

102 1/2013

Сахарный диабет Лекция

эффективности лечения пациентов с сахарным диабетом.

Consilium Medicum. 2012; 14(12):92–98.

15. U.K. prospective diabetes study 16. Overview of 6 years’ therapy

of type II diabetes: a progressive disease. U.K. Prospective Diabetes

Study Group. Diabetes. 1995; 44(11):1249–1258.

16. Stoffers D.A., Kieffer T.J., Hussain M.A., Drucker D.J., Bonner-

Weir S., Habener J.F., Egan J.M. Insulinotropic glucagon-like pep-

tide 1 agonists stimulate expression of homeodomain protein IDX-1

and increase islet size in mouse pancreas. // Diabetes. 2000;

49(5):741–748.

17. Drucker DJ. Glucagon-like peptides. Diabetes. 1998; 47(2):159–169.

18. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 pro-

motes satiety and suppresses energy intake in humans. J Clin Invest.

1998; 101(3):515–520. DOI: 10.1172/jci990.

19. Nauck MA, Wollschlager D, Werner J, Holst JJ, Orskov C,

Creutzfeldt W, Willms B. Effects of subcutaneous glucagon-like pep-

tide 1 (GLP-1 [7–36 amide]) in patients with NIDDM. Diabetologia.

1996; 39(12):1546–1553.

20. Larsson H, Holst JJ, Ahren B. Glucagon-like peptide-1 reduces he-

patic glucose production indirectly through insulin and glucagon in

humans. Acta Physiol Scand. 1997; 160(4):413–422.

21. Ilkova H, Glaser B, Tunçkale A, Bagriaçik N, Cerasi E. Induction of

Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic

Patients by Transient Intensive Insulin Treatment. Diabetes Care.

1997; 20(9):1353–1356. DOI: 10.2337/diacare.20.9.1353.

22. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E,

Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Manage-

ment of hyperglycaemia in type 2 diabetes: a patient-centered

approach. Position statement of the American Diabetes Association

(ADA) and the European Association for the Study of Diabetes

(EASD). Diabetologia. 2012; 55(6):1577–1596. DOI: 10.1007/

s00125-012-2534-0.

23. Hunt LM, Kreiner M, Brody H. The Changing Face of Chronic Illness

Management in Primary Care: A Qualitative Study of Underlying

Influences and Unintended Outcomes. The Annals of Family Medi-

cine. 2012; 10(5):452–460. DOI: 10.1370/afm.1380.

24. Fat and getting fatter: U.S. obesity rates to soar by 2030.

2012 [cited 2012 26.10.2012]; Available from: http://

www.reuters.com/article/2012/09/18/us-obesity-us-idUS-

BRE88H0RA20120918.

25. Eckel RH, Committee FtN. Obesity and heart disease: a statement

for healthcare professionals from the Nutrition Committee, Ameri-

can Heart Association. Circulation. 1997; 96(9):3248–3250. DOI:

10.1161/01.cir.96.9.3248.

26. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel

RH. Obesity and cardiovascular disease: pathophysiology, evalu-

ation, and effect of weight loss: an update of the 1997 American

Heart Association Scientific Statement on Obesity and Heart Dis-

ease from the Obesity Committee of the Council on Nutrition, Physi-

cal Activity, and Metabolism. Circulation. 2006; 113(6):898–918.

DOI: 10.1161/circulationaha.106.171016.

27. Krauss RM, Winston M, Fletcher BJ, Grundy SM. Obesity: Impact on

Cardiovascular Disease. Circulation. 1998; 98(14):1472–1476.

DOI: 10.1161/01.cir.98.14.1472.

28. Lionetti L, Mollica MP, Lombardi A, Cavaliere G, Gifuni G, Barletta

A. From chronic overnutrition to insulin resistance: The role of fat-

storing capacity and inflammation. Nutrition, Metabolism and Car-

diovascular Diseases. 2009; 19(2):146–152. DOI: 10.1016/j.

numecd.2008.10.010.

29. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a

risk factor for clinical diabetes mellitus in women. Ann Intern Med.

1995; 122(7):481–486.

30. Willett WC, Dietz WH, Colditz GA. Guidelines for Healthy Weight.

New England Journal of Medicine. 1999; 341(6):427–434. DOI:

doi:10.1056/NEJM199908053410607.

31. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes:

Scientific review. JAMA: The Journal of the American Medical Asso-

ciation. 2002; 287(3):360–372. DOI: 10.1001/jama.287.3.360.

32. Effect of intensive blood-glucose control with metformin on compli-

cations in overweight patients with type 2 diabetes (UKPDS 34).

UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;

352(9131):854–865.

33. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR,

Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B,

Viberti G. Glycemic Durability of Rosiglitazone, Metformin,

or Glyburide Monotherapy. New England Journal of Medi-

cine. 2006; 355(23):2427–2443. DOI: doi:10.1056/NEJ-

Moa066224.

34. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: random-

ized addition of glargine or human NPH insulin to oral therapy

of type 2 diabetic patients. Diabetes Care. 2003; 26(11):3080–

3086. DOI: 10.2337/diacare.26.11.3080.

35. Sjöström CD, Lissner L, Wedel H, Sjöström L. Reduction in Incidence

of Diabetes, Hypertension and Lipid Disturbances after Intentional

Weight Loss Induced by Bariatric Surgery: the SOS Intervention

Study. Obesity Research. 1999; 7(5):477–484. DOI: 10.1002/

j.1550-8528.1999.tb00436.x.

36. Bult MJF, van Dalen T, Muller AF. Surgical treatment of obesity. Eu-

ropean Journal of Endocrinology. 2008; 158(2):135–145. DOI:

10.1530/eje-07-0145.

37. Sjöström L, Lindroos A-K, Peltonen M, Torgerson J, Bouchard C,

Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sul-

livan M, Wedel H. Lifestyle, Diabetes, and Cardiovascular Risk

Factors 10 Years after Bariatric Surgery. New England Journal of

Medicine. 2004; 351(26):2683–2693. DOI: doi:10.1056/NEJ-

Moa035622.

38. Kashyap SR, Louis ES, Kirwan JP. Weight loss as a cure for Type 2

diabetes: fact or fantasy? Expert Review of Endocrinology & Me-

tabolism. 2011; 6(4):557–561. DOI: 10.1586/eem.11.42.

39. Yudkin JS, Richter B, Gale EAM. Intensified glucose lowering

in type 2 diabetes: time for a reappraisal. Diabetologia. 2010;

53(10):2079–2085. DOI: 10.1007/s00125-010-1864-z.

Левит Шмюэль MD, PhD, Институт эндокринологии и метаболизма, Медицинский центр Шеба, Тель-Авив,

Израиль

E-mail: shlevit@gmail.com

Филиппов Юрий Иванович научный сотрудник, отделение программного обучения и лечения, Институт диабета,

ФГБУ Эндокринологический научный центр, Москва, Россия

E-mail: yuriyivanovich@gmail.com

Горелышев Александр Сергеевич аспирант, отделение программного обучения и лечения, Институт диабета,

ФГБУ Эндокринологический научный центр, Москва, Россия

E-mail: sathandi@gmail.com

Сахарный диабет. 2013;(1):91–102

DMjournal.ru/ru/articles/catalog/2013_1/2013_1_91



Source: www.researchgate.net


Добавить комментарий